291,701 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Purchased by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. purchased a new position in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 291,701 shares of the company’s stock, valued at approximately $272,000. Jacobs Levy Equity Management Inc. owned about 0.41% of Ovid Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in OVID. SG Americas Securities LLC grew its holdings in shares of Ovid Therapeutics by 83.9% during the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock worth $35,000 after buying an additional 17,172 shares during the last quarter. Bank of America Corp DE boosted its holdings in Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares in the last quarter. Rhumbline Advisers boosted its holdings in Ovid Therapeutics by 22.3% in the 4th quarter. Rhumbline Advisers now owns 84,078 shares of the company’s stock valued at $79,000 after purchasing an additional 15,355 shares in the last quarter. Barclays PLC boosted its holdings in Ovid Therapeutics by 311.2% in the 3rd quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after purchasing an additional 63,702 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Ovid Therapeutics by 142.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company’s stock valued at $101,000 after purchasing an additional 63,200 shares in the last quarter. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Price Performance

OVID stock opened at $0.30 on Monday. The firm has a 50 day moving average of $0.33 and a 200-day moving average of $0.69. Ovid Therapeutics Inc. has a 12-month low of $0.24 and a 12-month high of $3.39. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The company has a market cap of $21.55 million, a price-to-earnings ratio of -0.64 and a beta of 0.27.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts expect that Ovid Therapeutics Inc. will post -0.4 EPS for the current fiscal year.

Analyst Ratings Changes

OVID has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $3.00 price objective (down previously from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a report on Wednesday, January 29th. William Blair raised Ovid Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. Finally, BTIG Research lowered their price objective on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Ovid Therapeutics has an average rating of “Buy” and a consensus target price of $3.03.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.